Hims & Hers Health Inc. (NYSE: HIMS), a telehealth company with a $6.1 billion valuation, has been a remarkable growth story, especially over the past year. The stock climbed an astounding 215% in 2024, significantly outperforming the broader market and its sector. This momentum has carried into 2025, with shares already up over 15% already year-to-date.
Short-term traders might be closely watching for further upward momentum, with the stock now consolidating bullishly below its 52-week highs. However, as the company faces increasing challenges, including a stretched valuation and rising competition, investors are left to determine whether HIMS is better suited for momentum trading or long-term ownership.
